ASMB May 2024 2.500 put
| Previous close | 1.5000 |
| Open | N/A |
| Bid | 1.4500 |
| Ask | 2.1000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 1.5000 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 50 |
ZacksAre Medical Stocks Lagging Entera Bio (ENTX) This Year?
Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
GlobeNewswireAssembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on track to initiate by mid-2024 ABI-5366 interim Phase 1a first-in-human data expected in Q3 2024 and ABI-4334 interim Phase 1b data expected by end of year SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovativ
ZacksAre Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
